The current or recent use of progestagen-only contraceptives is associated with an increased risk for developing breast cancer, irrespective of the mode of delivery, suggests research published in PLOS Medicine.
The addition of the oncolytic virus talimogene laherparepvec to neoadjuvant chemotherapy may increase responses in women with nonmetastatic triple-negative breast cancer, say phase 2 trial investigators.
US research points to disparities in the diagnosis, treatment, and outcomes of breast cancer in people belonging to minority groups with respect to sexual orientation and gender identity.
A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.
The 15-year data from the ProtecT trial show low rates of prostate cancer-specific mortality among men with prostate-specific antigen-detected, localized disease regardless of whether they received active monitoring, prostatectomy, or radiotherapy.
Patients with localized renal cell carcinoma at high risk for recurrence do not derive a significant disease-free survival benefit from the postoperative use of nivolumab plus ipilimumab versus placebo, shows the phase 3 CheckMate 914 study.
Phase 2 data point to the potential of switch maintenance with darolutamide in men with metastatic castration-resistant prostate cancer that has not progressed after taxane therapy.
A variant of the interleukin 7 gene is associated with an increased risk of immune-related adverse events in people with cancer receiving immune checkpoint inhibitor therapy, suggests research.
The overall survival benefit offered by immune checkpoint inhibitors in people with advanced non-small-cell lung cancer varies by age, suggests a real-world study.
More lung & thoracic cancers news
Stay informed with Medicine Matters
Get the latest developments in breast, lung, & GU cancers delivered straight to your inbox